UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 727,848 shares of the biopharmaceutical company’s stock after acquiring an additional 50,329 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Alnylam Pharmaceuticals were worth $219,104,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in ALNY. iA Global Asset Management Inc. grew its stake in Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares in the last quarter. SCS Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $50,773,000. Hsbc Holdings PLC lifted its holdings in shares of Alnylam Pharmaceuticals by 22.6% during the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after acquiring an additional 16,503 shares during the last quarter. Finally, Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $240.69 on Tuesday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $32.21 billion, a price-to-earnings ratio of 44.74 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The firm has a 50 day moving average of $261.71 and a 200 day moving average of $292.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the previous year, the business earned ($0.51) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% compared to the same quarter last year. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ALNY. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Bank of America reduced their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Citigroup decreased their target price on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. Barclays reduced their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Finally, Needham & Company LLC lowered their price target on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.